Core Viewpoint - The company aims to expand its international market presence while focusing on the growth and high-end transformation of the domestic pharmaceutical equipment industry [1] Group 1: Business Strategy - The company will continue to vigorously explore overseas markets, capitalizing on the export growth and high-end transformation trends in the domestic pharmaceutical equipment sector [1] - The company is committed to steadily advancing its globalization strategy to enhance the proportion of international business in its revenue [1] - The company plans to build a global high-end pharmaceutical equipment brand through independent technological innovation, product high-endization, and refined management [1] Group 2: Management Approach - The company will persist in implementing "quality improvement and efficiency enhancement" by leveraging technological means such as intelligent manufacturing to achieve smart upgrades in production [1] - Management measures will be employed to control various costs, including sales, finance, and management, to achieve cost reduction and efficiency improvement [1]

Core Viewpoint - The company, Chutian Technology, emphasizes its commitment to technological innovation and continuous product development since its establishment, maintaining a leading position in R&D investment within the industry [1] Group 1: Product Development and Innovation - The company has consistently launched new products and technologies in recent years, including continuous BFS, fully automatic intelligent lamp inspection machines, new transdermal drug delivery devices, pre-filled syringe and ampoule composite packaging solutions, automatic production lines for injection pens, and overall solutions for liquid nitrogen granulation freeze-drying [1] - The company plans to continue its "dual priority on product technology and manufacturing technology" strategy, aiming to enhance its overall technical solution capabilities and provide better products and services to downstream customers and the global pharmaceutical industry [1]

南财智讯1月26日电，楚天科技在投资者关系活动中表示，子公司德国ROMACO集团经管理团队调整优 化及业务协同深化后，经营状况逐步改善，核心业务指标及市场竞争力较2024年同期有所提升，为商誉 稳定性提供了支撑；最终商誉是否发生减值及减值金额，仍需以第三方资产评估机构及审计机构出具的 正式商誉减值测试报告为准，具体以公司后续披露的相关公告信息为准。 ...

证券代码：300358 证券简称：楚天科技 ③公司自 2024 年下半年，开展了一系列精细化管理措施，开 源节流，2025 年内公司整体运营成本得到有效控制，成果显著， 期间费用总额较 2024 年同期下降明显。 楚天科技股份有限公司 投资者关系活动记录表 编号：2026-001 | | 特定对象调研 □分析师会议 | | --- | --- | | | 媒体采访 □业绩说明会 | | 调研活动类别 | □新闻发布会 □路演活动 | | | 现场参观 其他 | | 时 间 | 2026 年 1 月 23 日上午 10:00-12:00，平安证券、国信证券自营、 | | | 毅木资产、湖南医药发展私募基金 | | 参与单位名称 | | | | 2026 年 1 月 26 日上午 10:30-12:00，招商证券 | | 地 点 | 公司会议室 | | 上市公司接待 | 董事会秘书：黄玉婷 | | 人员姓名 | 证券事务代表：周德伟 | | | 一、内容提要： | | | 1、厂区参观 | | | 2、会议室座谈 | | | 二、主要关注的问题与回复如下： | | | 1、公司 2025 年度业绩预告较 ...

Group 1: Chemical and Metal Industries - Several chemical companies, including Xinong Co. and Dayang Bio, are showing continuous improvement in their operations [1] - The non-ferrous metal sector benefits from high prices and capacity release, with Zijin Mining expected to achieve a net profit of 51 billion to 52 billion yuan in 2025, a year-on-year increase of 59% to 62% [1] - Zijin Mining's growth is driven by increased production and higher sales prices of gold, copper, and silver [1] - The high-end manufacturing sector shows resilience, with Okoyi's net profit projected to grow by 67.53% to 91.96% in 2025, despite rising raw material costs [1] - The new materials industry is also performing well, with China National Materials Technology expected to achieve a net profit of 1.55 billion to 1.95 billion yuan in 2025, a year-on-year increase of 73.79% to 118.64% [1] Group 2: International Market Growth - The overseas market is becoming a new growth engine for many listed companies [2] - Siyuan Electric is expected to achieve total revenue of 21.205 billion yuan in 2025, a year-on-year increase of 37.18%, and a net profit of 3.163 billion yuan, up 54.35% [2] - Absen, a leading global LED display provider, anticipates a net profit of 240 million to 290 million yuan in 2025, representing a year-on-year growth of 105.32% to 148.09% [2] - Absen's overseas revenue reached approximately 3.193 billion yuan, a year-on-year increase of about 8.94% [2] Group 3: Company-Specific Developments - Chutian Technology expects a net profit of 235 million to 300 million yuan in 2025, marking a turnaround to profitability driven by strong international market breakthroughs [3] - The company has made significant progress in Southeast Asia, the Middle East, and the Americas, with overseas sales revenue steadily increasing [3] - Hangcha Group is also expanding into emerging markets while consolidating its traditional markets, indicating the effectiveness of its globalization strategy [3]

Market Performance - The pharmaceutical sector experienced a decline of -1.18% on January 15, 2025, underperforming the CSI 300 index by 1.38 percentage points, ranking 25th among 31 sub-industries in the Shenwan classification [1] - Among sub-industries, other biological products (-0.04%), hospitals (-0.75%), and medical consumables (-0.77%) performed relatively well, while pharmaceutical distribution (-2.57%), medical devices (-2.51%), and offline pharmacies (-2.11%) lagged behind [1] - Top three gainers included Shanhe Pharmaceutical (+20.01%), Duori Pharmaceutical (+11.48%), and Yahong Pharmaceutical (+7.69%); top three losers were Sunflower (-20.00%), Hongbo Pharmaceutical (-20.00%), and Huaren Health (-19.99%) [1] Industry News - Ipsen announced that the FDA has granted breakthrough therapy designation for its investigational monoclonal antibody IPN60340, which is used in combination with Ven-Aza for the treatment of newly diagnosed acute myeloid leukemia (AML) patients who are not suitable for intensive therapy [2] - The designation is based on data from the Phase 1/2 EVICTION trial, showing that patients receiving the combination treatment had a nearly doubled complete remission rate compared to historical standard treatment data, particularly in subtypes that typically respond poorly to standard treatment [2] - IPN60340 targets BTN3A, a key immune regulatory molecule widely expressed in various cancers, promoting the recognition and elimination of tumor cells by γ9δ2 T cells [2] Company News - Saint Noble Bio (688117) announced an expected net profit attributable to shareholders of 152-190 million yuan for 2025, representing a year-on-year growth of 204.42%-280.53%, with a non-recurring net profit expected to be 149-186 million yuan, reflecting a growth of 226.07%-307.58% [3] - Yipinhong (300723) reported similar profit expectations for 2025, with a net profit forecast of 152-190 million yuan and a non-recurring net profit of 149-186 million yuan, both showing significant year-on-year growth [3] - Chutian Technology (300358) expects to achieve a net profit of 235-300 million yuan for 2025, marking a turnaround from losses in the previous year, with a non-recurring net profit forecast of 135-200 million yuan [3] - Ganli Pharmaceutical (603087) received approval from the Ethiopian National Food and Drug Administration for the registration of its insulin glargine injection and pre-filled pen, allowing for import and sale in Ethiopia [3]

Group 1 - The core viewpoint of the article is that Chutian Technology (300358) is currently focused on providing automated and intelligent overall solutions for global pharmaceutical clients [1] - The company's business and technological expansion revolves around three concentric circles: technology, customers, and products [1] - The company clarifies that it does not engage in the aforementioned business areas [1]

Core Viewpoint - The medical device sector experienced a decline of 1.58% on January 16, with Kangzhong Medical leading the losses, while the Shanghai Composite Index fell by 0.26% and the Shenzhen Component Index decreased by 0.18% [1]. Group 1: Market Performance - The medical device sector's stocks showed mixed performance, with notable gainers including Huakang Clean (20.01% increase) and Yirui Technology (4.60% increase) [1]. - Conversely, Kangzhong Medical saw a significant drop of 8.60%, followed by Huada Zhizao with a decline of 6.61% [2]. - The overall trading volume in the medical device sector was substantial, with Huakang Clean achieving a transaction amount of 707 million yuan [1]. Group 2: Capital Flow - The medical device sector experienced a net outflow of 1.395 billion yuan from major funds, while retail investors contributed a net inflow of 1.42 billion yuan [2]. - Specific stocks like Huakang Clean had a net inflow of 58.17 million yuan from major funds, while retail investors showed a net outflow of 46.88 million yuan [3]. - The capital flow dynamics indicate a shift in investor sentiment, with retail investors actively participating despite the overall sector decline [2][3].

经济观察网2026年1月15日，楚天科技（300358）发布2025年度业绩预告，预计2025年净利润2.35亿元 至3亿元，同比增长151.92%至166.28%；扣除非经常性损益后的净利润1.35亿元至2亿元，同比增长 127.38%至140.56%。 ...

Core Viewpoint - Chutian Technology (300358) is expected to return to profit growth in 2025, with projected net profit ranging from 235 million to 300 million yuan, following a loss of 453 million yuan in the previous year [1] Group 1: Financial Performance - The company anticipates a net profit of 135 million to 200 million yuan after excluding non-recurring gains and losses for 2025 [1] - For the first three quarters, Chutian Technology reported operating revenue of 3.896 billion yuan and a net profit attributable to shareholders of 84.46 million yuan, estimating a fourth-quarter net profit of 151 million to 215 million yuan [1] Group 2: Growth Drivers - The growth in performance is attributed to international market expansion, improved order quality, and cost reduction measures [1][2] - The company has seen a significant increase in the quality and gross margin of new order contracts during the reporting period [1] - Non-recurring gains and losses are expected to impact the 2025 net profit by approximately 100 million yuan [1] Group 3: International Market Expansion - Chutian Technology is intensifying its efforts in international market expansion, achieving breakthroughs in Southeast Asia, the Middle East, Africa, and the Americas, leading to a significant increase in the proportion of international business [1][2] - The company has segmented the global market into five regions to enhance local sales and service responsiveness [2] Group 4: Operational Strategies - Starting from the second half of 2024, the company will implement a differentiated competition strategy to enhance order quality and has initiated various cost reduction measures [2] - The company is optimizing product solutions in R&D, reducing procurement costs in the supply chain, and improving production efficiency, which has led to a noticeable increase in gross margin [2] - A series of refined management measures have been implemented to control overall operating costs, with total expenses significantly reduced compared to the previous year [2] Group 5: Future Outlook - Chutian Technology plans to continue expanding its overseas market presence while capitalizing on the growth and high-end transformation trends in the domestic pharmaceutical equipment industry [3] - The company aims to enhance the proportion of international business in its revenue and build a global high-end pharmaceutical equipment brand through innovation and product refinement [3]